ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49-51 55129 Mainz - Germany Phone: +49 (0) 61 31 / 92 58-0 Fax: +49 (0) 61 31 / 92 58-58 Internet: www.orgentec.com



Electronic Instruction For Use: version



ORG 270 25-OH Vitamin D₃/D₂

INTENDED PURPOSE

25-OH Vitamin D_3/D_2 for Alegria[®] is an ELISA based test system intended for the quantitative measurement of the total concentration of 25-(OH)-Vitamin D_2 and 25-(OH)-Vitamin D_3 in human serum or plasma samples (EDTA plasma, heparin plasma, citrate plasma). This product is intended for professional in vitro diagnostic use only. The concentration of 25-OH vitamin D is an indicator of the vitamin D supply in the body. Concentrations of 25-OH vitamin D over 20 ng/ml are considered to indicate a sufficient supply of vitamin D; values of 12-20 ng/ml indicate a lack of vitamin D; concentrations below 12 ng/ml indicate severe vitamin D deficiency. The level of 25-OH vitamin D correlates with the clinical symptoms of vitamin D deficiency.

SYMBOLS USED

| IVD | In vitro diagnostic medical device | | |
|-----------|---|---------------------|----------------------------------|
| *** | Manufacturer | ALEGRIA TEST STRIPS | Alegria [®] Test Strips |
| REF | Catalogue number | WASH | Wash Buffer |
| 24 | Sufficient for determinations | | System Fluid Ready to use |
| LOT | Batch code | | i iouuj io uoo |
| \square | Use by | | |
| 2°C | Temperature limitation | | |
| Ĩ | Consult instructions for use | | |
| 类 | Keep away from sunlight | | |
| \otimes | Do not reuse | | |
| \sim | Date of manufacture | | |
| CE | CE marked according to 98/79/EC | | |
| 270_5 | Electronic Instruction For Use: version | | |
| | | | |
| | | | |

PRINCIPLE OF THE TEST

The Alegria[®] assay features barcoded 8-well-microstrips, called Alegria[®] Test Strips. Each strip is designed for a single determination of one patient sample. The Alegria[®] Test Strip holds a complete set of reagents. Included are enzyme conjugate, enzyme substrate, sample buffer and a test specific control. Two wells of the Alegria[®] Test Strip are coated with a 25-OH vitamin D_3/D_2 antibody and serve as reaction wells for one control and one patient sample. Two more wells of the Alegria[®] Test Strip are coated with a 25-OH vitamin D control respectively.

The determination is based on a competitive enzyme linked immunosorbent assay (ELISA) with the following steps: The sample is pipetted into well No 1. Inside the Alegria[®] Random Access Analyser the sample is mixed with tracer reagent and the 25-OH vitamin D_3/D_2 is delivered from vitamin D binding protein. 25-OH vitamin D and tracer reagent coated in well No 2 are suspended with buffer. Sample and control are then transferred to the reaction wells No 3 and No 4 where 25-OH vitamin D_3/D_2 and 25-OH vitamin D tracer reagent compete for binding to the coated 25-OH vitamin D_3/D_2 antibody. Complexes are formed between 25-OH vitamin D_3/D_2 and antibody or 25-OH vitamin D tracer reagent and antibody. After incubation, a first washing step removes unbound and unspecifically bound molecules. Subsequently added enzyme conjugate binds to the immobilized tracer-antibody complexes. After incubation, a second washing step removes unbound enzyme conjugate. Addition of enzyme substrate solution results in hydrolisation and color development during incubation. The intensity of the blue color can be measured photometrically at 650 nm. The intensity of the blue color correlates inversely with the concentration of vitamin D in the sample.

The Alegria[®] Test Strip utilizes the proprietary SMC[®]-Technology (Sensotronic Memorized Calibration): information about the assay, analysis and evaluation, and the lot-specific expiry date is contained on the barcode printed on each Alegria[®] Test Strip.

The Alegria[®] Test Strip can be used with the diagnostic instrument Alegria[®] - a fully automated Random Access Analyser. By means of SMC[®]-Technology data encoded on the barcode are transferred from the Alegria[®] Test Strip to the instrument and the assay is automatically processed and evaluated. The instrument reads the date of expiry and rejects further processing if the Alegria[®] Test Strip is out of date.

WARNINGS AND PRECAUTIONS

- · All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- · System fluid contains acid, classifiaction is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove
 contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin,
 wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running
 water for at least 10 minutes. Get medical attention if necessary.
- · Personal precautions, protective equipment and emergency procedures:

Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
- Conditions to avoid: Since substrate solution is light-sensitive. Store Alegria [®] strips in the dark.
- · For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying controls and/or pooled sera.

CONTENTS OF THE KIT

| CONTE | N15 0F 1F | | | | | |
|------------|------------|----------|---|--|------------------------------------|--|
| ∑ 24 | ORG 270 | | Sufficient for | 24 detern | ninations | ns |
| ALEGRIA TE | EST STRIPS | 24 | Alegria [®] Te Well 1: Well 2: | st Strips a green; coa brown; co | re modul ated with ated with | dules of 8 wells each composed of: ith 25-OH Vitamin D tracer ith 25-OH Vitamin D tracer + 25-OH Vitamin D control |
| | | 99 | Wells 3 + 4: | coated with | th antibo | oody (reaction wells) |
| P | | 7 8 | Well 5: | Buffer: ye | llow. | |
| 1 2 | 3 4 5 6 | | Well 6: | Enzyme detergent | Conjugat preserv | pate; light red; containing HRP conjugate; PBS, BSA, ervative ProClin 0.05%. |
| | | | Well 7: | Matrix; op sodium az | aque; co tide 0.09 | containing human serum matrix, Tris, BSA, preservative 09%. |
| | | | Well 8: | TMB Sub | strate: cle | clear; containing 3,3', 5,5'- Tetramethylbenzidin. |
| | | | Antibodies o wells 3+4. | etecting 2 | 5-OH Vit | Vitamin $D_{\!_2}$ and 25-OH Vitamin $D_{\!_3}$ are bound to reaction |
| | | | Code on ba | code: | VitD | on printout: VitD3/D2 |
| WASH | | 1x 20 ml | Wash Buffe 50 x concen | r , containii trate | ng Tris, c | , detergent, preservative sodium azide 0.09%; |
| SYSTEM FLU | JID 1 | x 2.5 ml | System Flu | i d , contain | s acid; 1 | 1000 x concentrate |

1 Certificate of Analysis

STORAGE AND STABILITY

- Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store Alegria[®] Test Strips sealed and dessicated in the clip bag provided.
- Shelf life of the unopended test kit is **12** months from day of production. Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and System Fluid are stable for at least 30 days when stored at 2-8°C. Once transferred to the reagent container we recommend consumption on the same day.

MATERIALS REQUIRED

- Vortex mixer
- Pipettes for 80 µl
- · Measuring cylinder for 1000 ml and 2500 ml
- · Distilled or deionized water

AUXILLIARY REAGENTS

ORG 271 25-OH Vitamin D₃/D₂ Control Set

25-OH Vitamin D₃/D₂ Control Set is an external quality control material for the quantitative Alegria[®] 25-OH Vitamin D₃/D₂ assay. This product is intended for professional in vitro diagnostic use only.

The Control Set contains Control A und Control B 2.5 ml each with a defined concentration of 25-OH Vitamin D₃/D₂ (see label) in Tris 0.7%, NaCl 0.8% with human serum matrix, BSA 0.5% and sodium azid 0.09% as preservative. Ready to use. For 30 Determinations. Store ORG 271 at 2-8°C in the dark.

Unopened controls are stabil until expiry date (see label). Once opened use up within 4 months.

Procedure in the Alegria® assay: Pipette 80 µl control at the bottom of well 1 of the Alegria test strip. This Control Set is available separately.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Do not expose specimens to heat, sun, or strong light during storage and usage.
- · Avoid repetitive freezing and thawing of serum or plasma samples.

Testing of heat-inactivated sera is not recommended.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- All materials must be at room temperature (20-28°C) prior to use.
- · To avoid carryover or contamination, change the pipette tip between samples.

PREPARATION OF REAGENTS

WASH

Dilute the content of the Wash Buffer concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use. Transfer the diluted Wash Buffer into the instrument reagent container. If only one Alegria run is to be performed on one day we recommend transferring only 500 ml diluted Wash Buffer.

SYSTEM FLUID

Dilute the content of the System Fluid concentrate (1000x) with distilled or deionised water to a final volume of 2500 ml prior to use. Transfer the diluted System Fluid into the instrument reagent container.

ALEGRIA TEST STRIPS

Take the required number of Alegria® Test Strips out of the clip bag and let them reach room temperature (20-28° C). Do not remove foil covering the empty wells until you are ready to start the assay.

TEST PROCEDURE

Alegria® Test Strips with SMC® technology are used with the diagnostic instrument Alegria®. Detailed information about operating the instrument can be taken from the Instrument User Manual.

(1) Remove the foil from the empty wells 1 to 4 of the Alegria[®] Test Strip.

Do not remove foil with printed barcode, covering wells 5 to 8.

- (2) Pipette 80 ul undiluted patient sample (serum or plasma) or ready to use control ORG 271 at the bottom of well 1.
- (3) Insert the strip into the SysTray. (3) Insert the strip into the SysTray.

(4) Place loaded SysTrays into the correct position in the Alegria® instrument and start run. All further steps will be done automatically. The test run is completed when the instrument starts printing the results.

Caution: Alegria[®] Test Strips 25-OH Vitamin D₃/D₂ need a special performance and therefore

they cannot be combined with other Alegria® tests in the same run.



CALIBRATION

The calibration is traceable to the ID-LC/Tandem MS reference preparation REF!25OHD (Labquality, IQAS).





[]i]

CALCULATION OF RESULTS

By means of SMC[®] Technology (Sensotronic Memorized Calibration), all test data are transferred to the system through individual barcodes on the Alegria[®] Test Strip. Calculation and interpretation of results will be performed automatically.

PERFORMANCE CHARACTERISTICS

Measuring range

The calculation range of this Alegria® assay is 5 - 200 ng/ml

Interpretation of results

Suggested classification ranges of vitamin D status according to literature (Ref 5): (Conversion factors: 1ng/ml = 2.5 nmol/l; 1 nmol/l = 0.4 ng/ml)

| Deficiency: | < 12 ng/ml | (< 30 nmol/l) |
|----------------|------------------|-------------------|
| Insufficiency: | 12 - 20 ng/ml | (30 - 50 nmol/l) |
| Sufficiency: | > 20 - 150 ng/ml | (> 50 - 375 nmol/ |

Limitations of the Procedure

According to literature several reference ranges are suggested. Examples:

Ref 5

Deutsche Gesellschaft für Ernährung (DGE), (ÖGE), (SGE), (SVE), Referenzwerte für die Nährstoffzufuhr, Vitamin D. 2012; ISBN 978-3-86528-128-9).

Deficiency: <12 ng/ml; Insufficiency: 12-20 ng/ml; Sufficiency: >20-160 ng/ml; Hypervitaminosis 160-500 ng/ml Ref 9

Holick, M.F. Vitamin D deficiency. N. Engl. J.M. 2007, 357: 266-281.

Deficiency: <20 ng/ml; Insufficiency: 21-29 ng/ml; Sufficiency: >30 ng/ml; Intoxication >150 ng/ml Ref 16

National Osteoporosis Society 2013, Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. Deficiency: <12 ng/ml; Insufficiency: 12-20 ng/ml; Sufficiency: >20 ng/ml

According to the literature, factors such as nutrition, season, skin color, age or culture affect the normal 25-OH vitamin D levels.

The concentration ranges for the classification of vitamin D supply should be considered a recommendation. Each laboratory should establish its own ranges according to ISO 15189:2007 Requirements for quality and competence particular to medical laboratories or other applicable criteria.

Samples containing high levels 25-OH vitamin D were serially diluted to demonstrate the dynamic range of the

Linearity

assay. 25-OH vitamin D concentration for each dilution was calculated by means of SMC[®] Technology.

 Sample
 Dilution
 Observed
 Expected
 O/E

 1
 1:1
 170.2
 200.0
 85

 1:2
 101.6
 100.0
 102

 1:4
 44.6
 50.0
 89

| 1 | 1:1 | 170.2 | 200.0 | 85 |
|---|------|-------|-------|-----|
| | 1:2 | 101.6 | 100.0 | 102 |
| | 1:4 | 44.6 | 50.0 | 89 |
| | 1:8 | 21.7 | 25.0 | 87 |
| | 1:16 | 12.9 | 12.5 | 104 |
| 2 | 1:1 | 129.2 | 120.0 | 107 |
| | 1:2 | 62.6 | 60.0 | 104 |
| | 1:4 | 25.1 | 30.0 | 84 |
| | 1:8 | 15.3 | 15.0 | 102 |
| 3 | 1:1 | 58.5 | 62.6 | 94 |

| 1:2 | 28.5 | 31.3 | 91 |
|------|------|------|-----|
| 1:4 | 14.7 | 15.6 | 94 |
| 1:8 | 9.7 | 7.8 | 124 |
| 1:16 | 4.1 | 3.9 | 105 |

Detection limit

Smallest ammount of Vitamin D detectable

5 ng/ml

Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below. Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6

determinations in 5 different runs. Results for run-to-run precision are shown in the table below

| Intra-Assay | | | | Inter-Assay | | |
|-------------|---------|------|--|-------------|---------|------|
| Sample | Mean | % CV | | Sample | Mean | % CV |
| | [ng/ml] | % | | | [ng/ml] | % |
| 1 | 16.3 | 10.7 | | 1 | 16.5 | 14.7 |
| 2 | 50.1 | 6.1 | | 2 | 45.6 | 7.9 |
| 3 | 107.5 | 3.9 | | 3 | 98.9 | 4.2 |

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

Study results

In a comparative study 74 vitamin D serum samples from persons aged 8 to 89, 2/3 female and 1/3 male were analyzed. A high correlation was found between Alegria[®] 25-OH Vitamin D_3/D_2 and HPLC method: R = 0.91



Specificity

Specificity was determined by measurement of cross-reactivity to 25-OH vitamin D related substances. Cross-reactivity is stated in % relative to 25-OH Vitamin D_3 reactivity:

| 25-OH Vitamin D₃ | 100 % |
|--|---------|
| 25-OH Vitamin D ₂ | 100.4 % |
| Vitamin D ₃ (Cholecalciferol) | < 0.1 % |

Vitamin D₂ (Ergocalciferol) < 0.6 %

REFERENCES

- 1. Ashraf, A. et al. Threshold for effects of vitamin D deficiency on glucose metabolism in obese female African-American adolescents. J Clin Endocrinol Metab 94 (9):3200-3206, 2009.
- Baker, A. M. et al. A nested case-control study of midgestation vitamin D deficiency and risk of severe preeclampsia. J Clin Endocrinol Metab 95 (11):5105-5109, 2010.
- 3. Crew, K. D. et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2 (6):598-604, 2009.
- 4. Cutolo, M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford), 48 (3): 210-212, 2009
- 6. Garland, C.F. et al. Vitamin D for Cancer Prevention: Global Perspective. Ann. Epidemiol. 2009; 19: 468-483.
- Hayek J. El, G. Egeland, and H. Weiler. Vitamin D status of Inuit preschoolers reflects season and vitamin D intake. J Nutr 140 (10):1839-1845, 2010.
- 8. Holick, M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 116 (8):2062-2072, 2006.

9. Holick, M.F. Vitamin D deficiency. N. Engl. J.M. 2007, 357: 266-281.

- Holick, M.F. Sunlight and Vitamin D for bone health and prevention of autoimmune diseases, cancer and cardiovascular disease. Am. J.Clin. Nutr. 2004; 80: 1678-1688.
- 11. Hollis B.W. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am. J. Clin. Nutr. 2008; 88: 507S-10S.
- 12. Houghton L.A. and Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clin. Nutr. 2006; 84:694-697.
- 13. Jorde, R. et al. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 55 (3):792-798, 2010.
- 14. Kamen, D. L. and Alele, J. D. Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 17 (6):540-545, 2010.
- 15. Krasowski, M. D. Pathology consultation on vitamin D testing. Am J Clin Pathol 136 (4):507-514, 2011.
- 16.National Osteoporosis Society 2013, Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management.
- 17. Sen, D. and Ranganathan, P. Vitamin D in rheumatoid arthritis: panacea or placebo? Discov Med 14 (78):311-319, 2012.

Wen, H. and Baker, J. F. Vitamin D, immunoregulation, and rheumatoid arthritis. J Clin Rheumatol 17 (2):102-107, 2011.
 Zerwekh, J.E. Blood biomarkers of Vitamin D status, Am. J.Clin. Nutr. 2004; 87: 1087-91.

Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established.

Change Control

Former version: ORG 270_IFU_EN_QM130718_2016-01-21_4 Reason for revision: Introduction electronic IFU on homepage









